Cancer is the prominent cause of death due to its uncontrolled growth of cells (Kaur et al., 2022; Lang, Sood, Kaur, Arora, & Behl, 2021). As per WHO, around 10 million deaths were reported in 2020 (1 in 6 deaths) and approximately 400,000 children develop cancer every year. The most common cancers in 2020 were breast (2.26 million cases), lung (2.21 million cases), prostate (1.41 million cases), skin (non-melanoma) (1.20 million cases), and stomach (1.09 million cases) cancer. Among the most common cause of death in 2020 were lung (1.80 million deaths), colon and rectum (916,000 deaths), liver (830,000 deaths), stomach (769,000 deaths), and breast (685,000 deaths) cancer (WHO, 2023). The new cases of cancer worldwide in 2040 are estimated to reach 30.2 million (WHO, 2023). Anticancer drugs and surgery are being used as conventional treatment options for cancer treatment but these have undesirable off-target effects (Gu, Cui, Chen, Xiong, & Zhao, 2018). The toxicity of anticancer chemotherapy has limited their usage. Small drug molecules or biopharmaceuticals administered systemically at low doses are unable to show their desired intratumoral concentration whereas high doses pose a threat to the patients as the death of healthy cells is seen along with the expected significant tumor inhibition. For avoiding these toxicities various novel approaches such as oligonucleotides, monoclonal antibodies etc. have been developed but the main limitation is their restricted approval for clinical use as their safety and in vivo actions are still need to be ameliorated(Pacheco, Baiao, Ding, Cui, & Sarmento, 2023). PROTACs are hybrid small chimeric molecules. These are innovative, unique, revolutionary, and growing for the treatment of cancer over the last few years, as it target the selective degradation of proteins (Jaeger & Winter, 2020; Paiva & Crews, 2019; Schapira, Calabrese, Bullock, & Crews, 2019; Z. Wang et al., 2023; Yin & Hu, 2020). This is a promising, emerging technology in chemical biology as well as in drug discovery (Au, Wang, Sigua, & Qi, 2020; Ciulli, 2019; Mi, Li, Gu, Li, & Chen, 2023; Shoda et al., 2020; X. Sun et al., 2019). The work of PROTACs is through the ubiquitin-proteasome system (UPS) and recently more findings in the area of ubiquitin have led to the discovery of this novel approach (Chen et al., 2022; Connections, 2020). Intriguingly, the attention from traditional drug targets is shifted to PROTACs having a known role in eradicating disease and studies such as cancer (oncology), neurodegenerative disorders (neurology), virus infections (virology), TDM-2 (endocrinology), and immune disorders (Immunology) (K. Li & Crews, 2022; Vadukoot, 2022; P. Wang & Zhou, 2018; Y. Wang, Jiang, Feng, Liu, & Sun, 2020). PROTACs are defined as heterobifunctional molecules having two functional groups or active sites that are incorporated with three components. The first component is a ligand for binding with target protein; the second component is a ligand for binding with E3 ubiquitin ligase and the third one is a linker to conjugate these two ligands and having an appropriate size of 10 nm, targets the UPS to selectively degrade target proteins (Xin Li & Song, 2020; Liu, Peng, & Wei, 2022; Madan et al., 2022; Yi Zhang, Loh, Chen, & Mainolfi, 2019; H. Zhu, Wang, Zhang, Pan, & Zhang, 2023). The idea of PROTAC was originated in 2001 by Craig and colleagues. They targeted the ubiquitin ligase complex, Skp1-Cullin-F-box artificially (Békés, Langley, & Crews, 2022). The PROTACs are dumbbell-shaped catalytic in their mode of action or event-driven in pharmacology, specific, fast, and reversible (Konstantinidou et al., 2019; Madan et al., 2022; Park et al., 2021). PROTACs can be classified into generations based on their components. Types of PROTACs are discussed in Fig. 1 (Banik, Pedram, Wisnovsky, Riley, & Bertozzi, 1970; Connections, 2019; Y. Ding, Fei, & Lu, 2020; Gu et al., 2018; Ji et al., 2022; Lebraud, Wright, Johnson, & Heightman, 2016; Nalawansha & Crews, 2020; Nalawansha et al., 2019; Pettersson & Crews, 2019; Wan, Yan, Gao, & Liu, 2020; N. Yang et al., 2023; Xin Zhou, Dong, Zhang, Zheng, & Sun, 2020).